Company Profile

AARTI DRUGS LTD.

NSE : AARTIDRUGSBSE : 524348ISIN CODE : INE767A01016Industry : Pharmaceuticals & DrugsHouse : Aarti
BSE612.45-9.4 (-1.51 % )
PREV CLOSE (Rs.) 621.85
OPEN PRICE (Rs.) 620.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 11174
TODAY'S LOW / HIGH (Rs.)610.00 620.05
52 WK LOW / HIGH (Rs.)580 841.4
NSE612.20 -9.75 (-1.57 % )
PREV CLOSE(Rs.) 621.95
OPEN PRICE (Rs.) 621.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 612.20 (133 )
VOLUME 209653
TODAY'S LOW / HIGH(Rs.) 610.00 623.45
52 WK LOW / HIGH (Rs.)580 841.8

Company Profile

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.41
TTM EPS (Rs.) 24.86
P/E Ratio 24.63
Book Value (Rs.) 91.27
Face Value (Rs.) 10
MCap (Rs. in Mn) 56712.87
Price/Earning (TTM) 20.42
Price/Sales (TTM) 2.92
Price/Book (MRQ) 6.71
PAT Margin (%) 13.46
ROCE (%) 33.35
Incorporation Year : 1984

Management Info :

Prakash M Patil - Chairman Rashesh C Gogri - Managing Director

Registered Office :

Address : Plot No N 198,M I D C,Tarapur Village - Patembhi, Taluka Palghar,
Thane,
Maharashtra-401506

Phone : 022-24019025

Website : www.aartidrugs.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS More
13Oct10-13-2021$ Announcement under Regulation 30 (LODR)-Change in Directorate Announcement under Regulati
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors at its meeting held today appointed Shri Ankit Vikram Paleja (DIN: 06975564) as an Additional Director in the category of an Independent Director of the Company with effect from October 13, 2021 for the period of three years subject to approval of the Shareholders of the Company.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and..
11Oct10-11-2021$Aarti Drugs informs about loss of share certificates Aarti Drugs informs about lo
Aarti Drugs has informed that the Company has received information from Link Intime India, Registrar & Share Transfer Agent of the Company for Loss of share certificates.

The above information is a part of company’s filings submitted to BSE.

Aarti Drugs has informed that the Company has received informat..
28Sep09-28-2021$Aarti Drugs informs about analyst meet Aarti Drugs informs about an
Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, Aarti Drugs has informed that the officials of the Company will be attending the Investor Conference on September 28, 2021, as per enclosed details.

The above information is a part of company’s filings submitted to BSE.

Pursuant to the provisions of Regulation 30(6) of SEBI (Listing..
22Sep09-22-2021$Aarti Drugs informs about analyst meet analyst meet Aarti Drugs informs about an

Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, Aarti Drugs has informed that the officials of the Company will be attending the Investor Conference on September 22, 2021 with Phillip Capital (India). The copy of Investor Presentation-June 2021 to be shared with participants has already been uploaded on stock exchanges and is also available on the website of the Company at www.aartidrugs.co.in. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. The changes may happen due to exigencies on the part of Host/ Company.

The above information is a part of company’s filings submitted to BSE.


Pursuant to the provisions of Regulation 30(6) of SEBI (Listing..
30Aug08-30-2021$Aarti Drugs informs about analyst meet Aarti Drugs informs about an

Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, Aarti Drugs has informed that the officials of the Company will be meeting Investors/Analysts (Participants) to be held on August 30, 2021. The copy of Investor Presentation-June 2021 which will be shared with participants has already been uploaded on stock exchanges and is also available on website of the Company at www.aartidrugs.co.in. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. The changes may happen due to exigencies on the part of Participants / Company.

The above information is a part of company’s filings submitted to BSE.

Pursuant to the provisions of Regulation 30(6) of SEBI (Listing..
Financials More
Rs. in Millions
QTR Jun 21 ANNUAL 21
Net Profit455.42577
Gross Profit 600.4 3377
Operating Profit 759.14076.9
Net Sales 5057.919148.9
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 20746.95 (0.93%)
M.Cap ( in Cr)
44085.82
Ajanta Pharma (BSE)
 2215.40 (2.45%)
M.Cap ( in Cr)
19171.13
Sanofi India (BSE)
 8117.95 (0.35%)
M.Cap ( in Cr)
18696.14
Mercury Laboratories (BSE)
 718.00 (3.16%)
M.Cap ( in Cr)
86.16
Suven Pharma (BSE)
 533.95 (1.75%)
M.Cap ( in Cr)
13592.50
Shareholding Pattern More
PROMOTERS 60.12 %
NON-INSTITUTION 35.55 %
MUTUAL FUNDS/UTI 2.05 %
FI/BANKS/INSURANCE 0.04 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
F & O Quotes